Catinazzo Thomas, the Chief Financial Officer of Relay Therapeutics, Inc., has reported a sale of shares to cover tax obligations associated with restricted stock units (RSUs). This transaction, filed on October 30, 2026, is significant as it highlights the financial strategies employed by executives in the biotech industry.

Background

Relay Therapeutics, Inc. is a prominent player in the biotechnology sector, specifically classified under the standard industrial classification of Biological Products (No Diagnostic Substances) [2836]. The company is based in Cambridge, Massachusetts, and focuses on innovative therapies in the life sciences. The recent filing reflects the ongoing activities of Catinazzo Thomas, who has been active in managing his financial interests in the company.

What the Filing Says

According to the filing (accession number 0001193125-26-441690), Catinazzo sold 1,469 shares of common stock on October 28, 2026, at a price of $18.62 per share. This sale was specifically to cover income tax withholding obligations upon the vesting of 3,269 shares of RSUs on October 27, 2026. The filing notes, "The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs." Following this transaction, Catinazzo holds 103,665 shares.

Impact

This transaction may affect Relay Therapeutics' investor relations and perceptions of executive management's financial strategies. It underscores the importance of tax management in the biotech sector, where executives often receive compensation in the form of stock options and RSUs. The filing indicates a structured approach to handling tax liabilities, which could be seen as a responsible financial practice.

What's Next

The filing does not say what happens next.